Skip to search formSkip to main contentSkip to account menu

FKSI-15 Questionnaire

Known as: FKSI-15, Functional Assessment for Cancer Therapy-Kidney Symptom Index 
A 15 item questionnaire developed to assess the symptom burden for patients with kidney cancer.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma
Using phase 3 trial data for sunitinib versus interferon (IFN)‐α in treatment‐naive patients with metastatic renal cell carcinoma… 
2014
2014
Targeted therapies: Juggling combinations—not the way forward
Review
2014
Review
2014
Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
441^ Background: Previous studies have shown minimal impact of tyrosine kinase inhibitors on primary renal tumors. In this phase… 
2014
2014
Correlation between patient-reported fatigue and hemoglobin (Hgb) levels in metastatic renal cell carcinoma (mRCC) patients (pts) receiving sunitinib (SU).
418 Background: Low Hgb is linked with fatigue in cancer pts; however, the onset and severity of fatigue is multifactorial. The… 
Highly Cited
2013
Highly Cited
2013
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
Background:Axitinib demonstrated greater progression-free survival vs sorafenib in a phase III study of previously treated… 
Review
2013
Review
2013
Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors.
2011
2011
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma
IntroductionThe goal of the study was to determine the relationship of baseline Functional Assessment of Cancer Therapy–Kidney… 
2011
2011
Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
4504 Background: In a global, randomized, phase III trial of axitinib vs sorafenib as second-line therapy for mRCC (Rini et al… 
2010
2010
Can patient-reported kidney cancer–specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma?
6136 Background: Baseline health-related quality of life and symptom burden have been shown to be predictive of survival in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)